Work

An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics

Year: 2010

Type: review

Source: Journal of Pharmaceutical Sciences

DOI: 10.1002/jps.22097

Authors: Satish K. Singh, Nataliya Afonina, Michel Awwad, Karoline Bechtold-Peters, Jeffrey T. Blue, Danny Chou, Mary Cromwell, Hans-Juergen Krause, Hanns-Christian Mahler, Brian K. Meyer, Linda Narhi, Doug P. Nesta, Thomas Spitznagel

Institutions: Pfizer (United States), Bristol-Myers Squibb (United States), Boehringer Ingelheim (Germany), Merck & Co., Inc., Rahway, NJ, USA (United States), Genentech, Abbott (Germany), F. Hoffmann-La Roche AG, Amgen (United States), GlaxoSmithKline (United States), Human Genome Sciences (United States)

Language: English

Topic: Protein purification and stability

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2122748934

FWCI: 2.348

Cites: 27

Cited by: 339

Related to: 10